相关实验视频
Updated: Jul 12, 2026

08:30
Use of a Hanging Weight System for Coronary Artery Occlusion in Mice
Published on: April 19, 2011
激活A2A-腺素受体的抗心脏病缓解作用主要是由于它对淋巴细胞的作用
Zequan Yang1, Yuan-Ji Day, Marie-Claire Toufektsian
1Department of Biomedical Engineering, of Virginia Health System, Charlottesville 22903, USA. zy6b@virginia.edu
Circulation
|April 27, 2005
概括
用ATL146e激活腺A2A受体 (A2AAR) 通过向骨髓衍生细胞 (如淋巴细胞) 来减少心脏病发作的大小. 这一发现澄清了A2AARAR背后的机制.
科学领域:
- 心血管研究研究心血管研究
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 缺血后的腺氨酸A2A受体 (A2AAR) 激活可以限制心肌梗塞的大小.
- 在A2AAR的心脏保护作用的基础上,确切的细胞机制仍然不完全理解.
研究的目的:
- 为了阐明A2AAR激活的细胞点,负责减少心脏病发作的大小.
- 研究骨髓衍生细胞在A2AAR激动剂治疗效果中的作用.
主要方法:
- 化学小鼠模型 (骨髓移植) 用于追踪细胞起源.
- 选择性A2AAR激动剂 (ATL146e) 在诱导心肌缺血后的再注血期间被施用.
- 量化了心脏病发作的大小和炎症标志物 (骨髓氧化酶).
主要成果:
- 在野生型小鼠中,ATL146e显著降低了心脏病发作的大小和髓氧化酶活性.
- 这些保护作用在A2AAR-Knockout小鼠和使用选择性抗剂时被废除.
- 骨髓衍生细胞,特别是淋巴细胞被确定为ATL146e中风缓解作用的关键调解者.
结论:
- 在骨髓衍生细胞,特别是T和B淋巴细胞上A2AAR激活,调解ATL146e的抗心脏病和抗炎作用.
- 这些发现突出了A2AAR介导的心脏保护在再输伤害期间的免疫细胞基机制.
相关概念视频
Adrenergic Receptors: ɑ Subtype
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Receptors: β Subtype
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...

